Header Logo

Connection

Mark Pollack to Psychiatric Status Rating Scales

Back to Details
This is a "connection" page, showing publications Mark Pollack has written about Psychiatric Status Rating Scales.
Mark Pollack
Connection Strength
2.291
Psychiatric Status Rating Scales
  1. Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale. Contemp Clin Trials. 2015 Jul; 43:223-30.
    View in: PubMed
    Score: 0.116
  2. Sleep quality predicts treatment outcome in CBT for social anxiety disorder. Depress Anxiety. 2013 Nov; 30(11):1114-20.
    View in: PubMed
    Score: 0.102
  3. D-Cycloserine as an augmentation strategy with cognitive-behavioral therapy for social anxiety disorder. Am J Psychiatry. 2013 Jul; 170(7):751-8.
    View in: PubMed
    Score: 0.101
  4. Culturally adapted CBT (CA-CBT) for Latino women with treatment-resistant PTSD: a pilot study comparing CA-CBT to applied muscle relaxation. Behav Res Ther. 2011 Apr; 49(4):275-80.
    View in: PubMed
    Score: 0.086
  5. Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial. J Clin Psychiatry. 2010 May; 71(5):627-31.
    View in: PubMed
    Score: 0.079
  6. Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry. 2010 Feb 15; 67(4):365-70.
    View in: PubMed
    Score: 0.078
  7. Next-step strategies for panic disorder refractory to initial pharmacotherapy: a 3-phase randomized clinical trial. J Clin Psychiatry. 2009 Nov; 70(11):1563-70.
    View in: PubMed
    Score: 0.078
  8. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res. 2008 Oct; 42(14):1176-84.
    View in: PubMed
    Score: 0.070
  9. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008 Oct; 42(12):1042-9.
    View in: PubMed
    Score: 0.069
  10. The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol. 2007 Feb; 27(1):85-8.
    View in: PubMed
    Score: 0.065
  11. The relationship of anxiety disorders, anxiety sensitivity and pulmonary dysfunction with dyspnea-related distress and avoidance. J Nerv Ment Dis. 2006 Dec; 194(12):951-7.
    View in: PubMed
    Score: 0.064
  12. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006 Mar; 67(3):381-5.
    View in: PubMed
    Score: 0.061
  13. Persistent posttraumatic stress disorder following September 11 in patients with bipolar disorder. J Clin Psychiatry. 2006 Mar; 67(3):394-9.
    View in: PubMed
    Score: 0.061
  14. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005 Nov; 66(11):1401-8.
    View in: PubMed
    Score: 0.060
  15. Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2004 Dec; 161(12):2222-9.
    View in: PubMed
    Score: 0.056
  16. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry. 2004 Sep; 65(9):1219-22.
    View in: PubMed
    Score: 0.055
  17. History of childhood abuse in panic disorder, social phobia, and generalized anxiety disorder. J Nerv Ment Dis. 2002 Jul; 190(7):453-6.
    View in: PubMed
    Score: 0.047
  18. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry. 2001 May; 62(5):350-7.
    View in: PubMed
    Score: 0.044
  19. Sertraline treatment of panic disorder: response in patients at risk for poor outcome. J Clin Psychiatry. 2000 Dec; 61(12):922-7.
    View in: PubMed
    Score: 0.042
  20. Quality of life in patients with panic disorder. J Nerv Ment Dis. 1999 Jul; 187(7):429-34.
    View in: PubMed
    Score: 0.038
  21. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998 Nov; 55(11):1010-6.
    View in: PubMed
    Score: 0.037
  22. Social phobia: an update. Harv Rev Psychiatry. 1998 Jan-Feb; 5(5):247-59.
    View in: PubMed
    Score: 0.035
  23. Nefazodone for social phobia: a clinical case series. Depress Anxiety. 1998; 8(3):131-3.
    View in: PubMed
    Score: 0.035
  24. Negative Posttrauma Cognitions Mediate the Association Between Morally Injurious Events and Trauma-Related Psychopathology in Treatment-Seeking Veterans. J Trauma Stress. 2017 12; 30(6):698-703.
    View in: PubMed
    Score: 0.034
  25. Prevalence of body dysmorphic disorder in patients with anxiety disorders. J Anxiety Disord. 1997 Sep-Oct; 11(5):499-502.
    View in: PubMed
    Score: 0.034
  26. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone. J Clin Psychiatry. 1997; 58 Suppl 11:19-23.
    View in: PubMed
    Score: 0.032
  27. Relationship of childhood anxiety to adult panic disorder: correlates and influence on course. Am J Psychiatry. 1996 Mar; 153(3):376-81.
    View in: PubMed
    Score: 0.030
  28. Prevalence of panic in patients referred for pulmonary function testing at a major medical center. Am J Psychiatry. 1996 Jan; 153(1):110-3.
    View in: PubMed
    Score: 0.030
  29. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry. 1994 May; 55(5):200-5.
    View in: PubMed
    Score: 0.027
  30. Anxiety psychopathology predictive of outcome in patients with panic disorder and depression treated with imipramine, alprazolam and placebo. J Affect Disord. 1994 Apr; 30(4):273-81.
    View in: PubMed
    Score: 0.027
  31. Influence of RGS2 on sertraline treatment for social anxiety disorder. Neuropsychopharmacology. 2014 May; 39(6):1340-6.
    View in: PubMed
    Score: 0.026
  32. Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder. J Clin Psychopharmacol. 1993 Aug; 13(4):257-63.
    View in: PubMed
    Score: 0.025
  33. Voxel-based morphometric gray matter correlates of posttraumatic stress disorder. J Anxiety Disord. 2013 May; 27(4):413-9.
    View in: PubMed
    Score: 0.025
  34. Augmentation of exposure therapy with post-session administration of D-cycloserine. J Psychiatr Res. 2013 Feb; 47(2):168-74.
    View in: PubMed
    Score: 0.024
  35. Personality disorders in patients with panic disorder: association with childhood anxiety disorders, early trauma, comorbidity, and chronicity. Compr Psychiatry. 1992 Mar-Apr; 33(2):78-83.
    View in: PubMed
    Score: 0.023
  36. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial. J Clin Psychiatry. 2012 Mar; 73(3):353-7.
    View in: PubMed
    Score: 0.022
  37. The role of anxiety sensitivity in sleep disturbance in panic disorder. J Anxiety Disord. 2011 May; 25(4):536-8.
    View in: PubMed
    Score: 0.021
  38. Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery. CNS Neurosci Ther. 2012 Jan; 18(1):21-7.
    View in: PubMed
    Score: 0.021
  39. Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry. 1990 Dec; 51 Suppl A:12-6.
    View in: PubMed
    Score: 0.021
  40. Anger, PTSD, and the nuclear family: a study of Cambodian refugees. Soc Sci Med. 2009 Nov; 69(9):1387-94.
    View in: PubMed
    Score: 0.019
  41. A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders. Brain Stimul. 2008 Apr; 1(2):112-21.
    View in: PubMed
    Score: 0.018
  42. Redefining affective disorders: relevance for drug development. CNS Neurosci Ther. 2008; 14(1):2-9.
    View in: PubMed
    Score: 0.017
  43. Complicated grief and impaired sleep in patients with bipolar disorder. Bipolar Disord. 2007 Dec; 9(8):913-7.
    View in: PubMed
    Score: 0.017
  44. Anxiety is associated with impulsivity in bipolar disorder. J Anxiety Disord. 2008 Jun; 22(5):868-76.
    View in: PubMed
    Score: 0.017
  45. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol. 2008 Mar; 18(3):230-3.
    View in: PubMed
    Score: 0.017
  46. Cross-cultural differences in somatic presentation in patients with generalized anxiety disorder. J Nerv Ment Dis. 2006 Dec; 194(12):962-6.
    View in: PubMed
    Score: 0.016
  47. Prospective 12-month course of bipolar disorder in out-patients with and without comorbid anxiety disorders. Br J Psychiatry. 2006 Jul; 189:20-5.
    View in: PubMed
    Score: 0.016
  48. Prefrontal and temporal gray matter density decreases in opiate dependence. Psychopharmacology (Berl). 2006 Jan; 184(2):139-44.
    View in: PubMed
    Score: 0.015
  49. Anxiety sensitivity in traumatized Cambodian refugees: a discriminant function and factor analytic investigation. Behav Res Ther. 2005 Dec; 43(12):1631-43.
    View in: PubMed
    Score: 0.015
  50. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005 Sep; 62(9):1022-30.
    View in: PubMed
    Score: 0.015
  51. Complicated grief and its correlates in patients with bipolar disorder. J Clin Psychiatry. 2005 Sep; 66(9):1105-10.
    View in: PubMed
    Score: 0.015
  52. Childhood antecedents to panic disorder in referred and nonreferred adults. J Child Adolesc Psychopharmacol. 2005 Aug; 15(4):549-61.
    View in: PubMed
    Score: 0.015
  53. Clinical and diagnostic implications of lifetime attention-deficit/hyperactivity disorder comorbidity in adults with bipolar disorder: data from the first 1000 STEP-BD participants. Biol Psychiatry. 2005 Jun 01; 57(11):1467-73.
    View in: PubMed
    Score: 0.014
  54. Does recovery from substance use disorder matter in patients with bipolar disorder? J Clin Psychiatry. 2005 Jun; 66(6):730-5; quiz 808-9.
    View in: PubMed
    Score: 0.014
  55. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl). 2005 Jan; 177(3):280-8.
    View in: PubMed
    Score: 0.014
  56. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004 Apr; 24(2):141-9.
    View in: PubMed
    Score: 0.013
  57. Prevalence and correlates of panic attacks in postmenopausal women: results from an ancillary study to the Women's Health Initiative. Arch Intern Med. 2003 Sep 22; 163(17):2041-50.
    View in: PubMed
    Score: 0.013
  58. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000 Aug; 20(4):467-71.
    View in: PubMed
    Score: 0.010
  59. History of childhood attention deficit hyperactivity disorder (ADHD) features among adults with panic disorder. J Affect Disord. 2000 May; 58(2):99-106.
    View in: PubMed
    Score: 0.010
  60. Cell-surface expression of L-selectin (CD62L) by blood lymphocytes: correlates with affective parameters and severity of panic disorder. Depress Anxiety. 2000; 11(1):31-7.
    View in: PubMed
    Score: 0.010
  61. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry. 1999 May; 156(5):756-60.
    View in: PubMed
    Score: 0.009
  62. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998 Nov; 155(11):1570-7.
    View in: PubMed
    Score: 0.009
  63. Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder. Psychopharmacol Bull. 1998; 34(2):199-205.
    View in: PubMed
    Score: 0.009
  64. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997 Aug; 17(4):247-54.
    View in: PubMed
    Score: 0.008
  65. EEG abnormalities in patients with atypical panic attacks. J Clin Psychiatry. 1995 Aug; 56(8):358-62.
    View in: PubMed
    Score: 0.007
  66. Alcohol dependence in panic disorder patients. J Psychiatr Res. 1992 Jan; 26(1):29-38.
    View in: PubMed
    Score: 0.006
  67. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry. 1991 Feb; 52(2):69-76.
    View in: PubMed
    Score: 0.005
  68. Clonazepam for the treatment of social phobia. J Clin Psychiatry. 1990 Nov; 51(11):470-2.
    View in: PubMed
    Score: 0.005
  69. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand. 1990 May; 81(5):432-6.
    View in: PubMed
    Score: 0.005
  70. Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant. J Psychiatr Res. 1990; 24(2):177-84.
    View in: PubMed
    Score: 0.005
  71. Clonazepam versus alprazolam in the treatment of panic disorder: interim analysis of data from a prospective, double-blind, placebo-controlled trial. J Clin Psychiatry. 1987 Oct; 48 Suppl:16-21.
    View in: PubMed
    Score: 0.004
  72. Enhancement of ECT benefit by yohimbine. J Clin Psychiatry. 1986 Oct; 47(10):508-10.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.